

Ning-Yu Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8890678/publications.pdf>

Version: 2024-02-01

51
papers

1,127
citations

394286

19
h-index

414303

32
g-index

56
all docs

56
docs citations

56
times ranked

1836
citing authors

#	ARTICLE	IF	CITATIONS
1	The Anthelmintic Drug Niclosamide Induces Apoptosis, Impairs Metastasis and Reduces Immunosuppressive Cells in Breast Cancer Model. PLoS ONE, 2014, 9, e85887.	1.1	101
2	Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasis. Cell Death and Disease, 2018, 8, e2534-e2534.	2.7	72
3	Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2. Journal of Medicinal Chemistry, 2021, 64, 2829-2848.	2.9	72
4	Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma. Scientific Reports, 2016, 6, 20253.	1.6	61
5	Inhibition of FGFR signaling by PD173074 improves antitumor immunity and impairs breast cancer metastasis. Breast Cancer Research and Treatment, 2014, 143, 435-446.	1.1	57
6	Synthesis and structure-activity relationships evaluation of benzothiazinone derivatives as potential anti-tubercular agents. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4919-4922.	1.0	55
7	Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer. Scientific Reports, 2016, 6, 20864.	1.6	46
8	Discovery and structure-activity relationships study of novel thieno[2,3-b]pyridine analogues as hepatitis C virus inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1581-1588.	1.0	43
9	Discovery of Imidazo[2,1-b]thiazole HCV NS4B Inhibitors Exhibiting Synergistic Effect with Other Direct-Acting Antiviral Agents. Journal of Medicinal Chemistry, 2015, 58, 2764-2778.	2.9	40
10	Synthesis and antitubercular evaluation of 4-carbonyl piperazine substituted 1,3-benzothiazin-4-one derivatives. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1373-1376.	1.0	39
11	YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect. Cell Death and Disease, 2018, 9, 1066.	2.7	38
12	SKLB316, a novel small-molecule inhibitor of cell-cycle progression, induces G2/M phase arrest and apoptosis in vitro and inhibits tumor growth in vivo. Cancer Letters, 2014, 355, 297-309.	3.2	34
13	Mannosylated liposomes improve therapeutic effects of paclitaxel in colon cancer models. Journal of Microencapsulation, 2017, 34, 513-521.	1.2	34
14	A Novel Cinnamide YLT26 Induces Breast Cancer Cells Apoptosis via ROS-Mitochondrial Apoptotic Pathway in Vitro and Inhibits Lung Metastasis in Vivo. Cellular Physiology and Biochemistry, 2014, 34, 1863-1876.	1.1	32
15	Benzothiazinethione is a potent preclinical candidate for the treatment of drug-resistant tuberculosis. Scientific Reports, 2016, 6, 29717.	1.6	31
16	Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors. European Journal of Medicinal Chemistry, 2020, 191, 112152.	2.6	31
17	Identification of novel 2-aminothiazole conjugated nitrofurans as antitubercular and antibacterial agents. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3669-3674.	1.0	27
18	Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor. European Journal of Medicinal Chemistry, 2022, 227, 113922.	2.6	24

#	ARTICLE	IF	CITATIONS
19	A Novel Small-Molecule YLT205 Induces Apoptosis in Human Colorectal Cells via Mitochondrial Apoptosis Pathway In Vitro and Inhibits Tumor Growth In Vivo. <i>Cellular Physiology and Biochemistry</i> , 2014, 33, 933-944.	1.1	22
20	Synthesis and biological evaluation of (E)-4-(3-arylvinyl-1H-indazol-6-yl)pyrimidin-2-amine derivatives as PLK4 inhibitors for the treatment of breast cancer. <i>RSC Advances</i> , 2017, 7, 27737-27746.	1.7	21
21	Structural and functional studies on <i>Pseudomonas aeruginosa</i> DspI: implications for its role in DSF biosynthesis. <i>Scientific Reports</i> , 2018, 8, 3928.	1.6	20
22	Design, synthesis and biological evaluation of novel 1-methyl-3-oxo-2,3,5,6,7,8-hexahydroisoquinolins as potential EZH2 inhibitors. <i>RSC Advances</i> , 2015, 5, 25967-25978.	1.7	15
23	Novel Dual BET and PLK1 Inhibitor WNY0824 Exerts Potent Antitumor Effects in CRPC by Inhibiting Transcription Factor Function and Inducing Mitotic Abnormality. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1221-1231.	1.9	15
24	Discovery of novel N-(5-(tert-butyl)isoxazol-3-yl)-N ² -phenylurea analogs as potent FLT3 inhibitors and evaluation of their activity against acute myeloid leukemia in vitro and in vivo. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 4333-4343.	1.4	14
25	Selective and efficient synthesis of trans-arylvinylboronates and trans-hetarylvinylboronates using palladium catalyzed cross-coupling. <i>New Journal of Chemistry</i> , 2017, 41, 3172-3176.	1.4	14
26	Synthesis and biological evaluation of N-(4-phenylthiazol-2-yl)cinnamamide derivatives as novel potential anti-tumor agents. <i>MedChemComm</i> , 2015, 6, 1036-1042.	3.5	12
27	Design, synthesis and biological evaluations of a series of Pyrido[1,2-a]pyrimidinone derivatives as novel selective FGFR inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2021, 220, 113499.	2.6	12
28	Small Molecule TH-39 Potentially Targets Hec1/Nek2 Interaction and Exhibits Antitumor Efficacy in K562 Cells via G0/G1 Cell Cycle Arrest and Apoptosis Induction. <i>Cellular Physiology and Biochemistry</i> , 2016, 40, 297-308.	1.1	11
29	ZLD1122, a novel EZH2 and EZH1 small molecular inhibitor, blocks H3K27 methylation and diffuse large B cell lymphoma cell growth. <i>RSC Advances</i> , 2016, 6, 28512-28521.	1.7	11
30	A new series of HCV inhibitors based on a 2-(thieno[2,3b]pyridin-2-yl)-1,3,4-oxadiazole scaffold. <i>RSC Advances</i> , 2016, 6, 40277-40286.	1.7	11
31	Structure-Function Relationship of Aminopeptidase P from <i>Pseudomonas aeruginosa</i> . <i>Frontiers in Microbiology</i> , 2017, 8, 2385.	1.5	11
32	Synthesis and biological evaluation of (1,2,4)triazole[4,3-a]pyridine derivatives as potential therapeutic agents for concanavalin A-induced hepatitis. <i>European Journal of Medicinal Chemistry</i> , 2019, 179, 182-195.	2.6	11
33	A novel benzothiazole derivative SKLB826 inhibits human hepatocellular carcinoma growth via inducing G2/M phase arrest and apoptosis. <i>RSC Advances</i> , 2015, 5, 41341-41351.	1.7	9
34	Design, synthesis and biological evaluation of 7-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-2,3-dihydro-1H-inden-1-one derivatives as potent FAK inhibitors for the treatment of ovarian cancer. <i>European Journal of Medicinal Chemistry</i> , 2022, 228, 113978.	2.6	9
35	Covalent inhibitors of EZH2: Design, synthesis and evaluation. <i>Biomedicine and Pharmacotherapy</i> , 2022, 147, 112617.	2.5	7
36	Identification of a potent and selective phosphatidylinositol 3-kinase β inhibitor for the treatment of non-Hodgkin's lymphoma. <i>Bioorganic Chemistry</i> , 2020, 105, 104344.	2.0	6

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetic Studies of a Novel Multikinase Inhibitor for Treating Cancer by HPLC-UV. <i>Journal of Chromatographic Science</i> , 2013, 51, 17-20.	0.7	5
38	A novel benzothiazinethione analogue SKLB-TB1001 displays potent antimycobacterial activities in a series of murine models. <i>Biomedicine and Pharmacotherapy</i> , 2017, 88, 603-609.	2.5	4
39	Metabolism of SKLB-TB1001, a Potent Antituberculosis Agent, in Animals. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	4
40	Design, synthesis and biological evaluation of 3,5-dimethylisoxazole and pyridone derivatives as BRD4 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 126577.	1.0	4
41	The New Convenient Synthesis of 6-Fluoropurine and Its 7-/9-Unsubstituted Analogues. <i>Heterocycles</i> , 2012, 85, 2999.	0.4	3
42	Preclinical Evaluation of Amphihevir, a First-in-Class Clinical Hepatitis C Virus NS4B Inhibitor. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	3
43	Design, synthesis and structure-activity relationship study of piperazinone-containing thieno[3,2-d]pyrimidine derivatives as new PI3K γ inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127479.	1.0	3
44	Synthesis and biological evaluation of N-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)benzenesulfonamide derivatives as new BET bromodomain inhibitors for anti-hematologic malignancies activities. <i>Molecular Diversity</i> , 2017, 21, 125-136.	2.1	2
45	Structural characterization of a β -enoyl-CoA isomerase from <i>Pseudomonas aeruginosa</i> : implications for its involvement in unsaturated fatty acid metabolism. <i>Journal of Biomolecular Structure and Dynamics</i> , 2019, 37, 2695-2702.	2.0	2
46	A novel small-molecule YLT256 inhibits proliferation and induces apoptosis both in vitro and in vivo in solid tumors. <i>Biomedicine and Pharmacotherapy</i> , 2016, 81, 482-490.	2.5	1
47	A novel benzoxazinone derivative YLT-LL-11 inhibits diffuse large B-cell lymphoma growth via inducing cell cycle arrest and apoptosis. <i>Bioscience Reports</i> , 2019, 39, .	1.1	1
48	6-Chloro-9-(2-nitrophenylsulfonyl)-9H-purine. <i>Acta Crystallographica Section E: Structure Reports Online</i> , 2011, 67, o687-o687.	0.2	0
49	9-Sulfonyl-9(H)-Purine Derivatives Inhibit HCV Replication Via their Degradation Species. <i>Pharmaceutical Chemistry Journal</i> , 2021, 55, 36-45.	0.3	0
50	BRD4 inhibition sensitizes aggressive non-Hodgkin lymphomas to PI3K γ inhibitors by suppressing PI3K reactivation and c-MYC expression. <i>American Journal of Cancer Research</i> , 2021, 11, 215-235.	1.4	0
51	A novel fixed-dose combination treatment for chronic hepatitis C, based on NS5A inhibitor fopitasvir and NS5B inhibitor sofosbuvir. <i>Die Pharmazie</i> , 2021, 76, 372-378.	0.3	0